Phase I trial of docetaxel, cisplatin and concurrent radical radiotherapy in locally advanced oesophageal cancer
2011

Trial of Docetaxel and Cisplatin with Radiotherapy for Oesophageal Cancer

Sample size: 24 publication Evidence: moderate

Author Information

Author(s): Day F L, Leong T, Ngan S, Thomas R, Jefford M, Zalcberg J R, Rischin D, McKendick J, Milner A D, Di Iulio J, Matera A, Michael M

Primary Institution: Peter MacCallum Cancer Centre

Hypothesis

What is the maximum tolerated dose of a novel weekly docetaxel and cisplatin regimen concurrent with radical radiotherapy in locally advanced oesophageal cancer?

Conclusion

Cisplatin and docetaxel each 30 mg/m² per week concurrent with 50 Gy radiotherapy is recommended for use in phase II clinical trials in oesophageal cancer.

Supporting Evidence

  • 24 patients were enrolled in the trial.
  • Two dose-limiting toxicities were observed: grade 3 fever and grade 3 nausea.
  • The overall response rate to treatment was 50%.

Takeaway

Doctors tested a new treatment for a type of throat cancer and found a safe dose that can help patients.

Methodology

Patients with unresectable, non-metastatic locally advanced oesophageal cancer received weekly docetaxel and cisplatin along with radiotherapy, with dose levels adjusted based on toxicity.

Limitations

The study was not powered to demonstrate improvements in cancer outcomes and had a small sample size.

Participant Demographics

Median age was 58 years, with 92% male and a mix of squamous cell carcinoma and adenocarcinoma histologies.

Statistical Information

Confidence Interval

95% CI 0.75–6.81 years for progression-free survival

Digital Object Identifier (DOI)

10.1038/sj.bjc.6606051

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication